Inhibitors of Ras farnesylation: Tomorrow's anticancer agents?;Inhibiteurs de farnesylation de Ras: Agents anticancereux de demain

Bulletin du Cancer

Volumn 84, Issue 6, 1997, Pages 635-642

  Perrin, Dominique ^a   Halazy, Serge ^a   Hill, Bridget ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Anticancer agents; Farnesyl protein transferase; Ras

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA GLUTAMYLTRANSFERASE; GERANYLTRANSFERASE; MANUMYCIN; NATURAL PRODUCT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYROPHOSPHORIC ACID DERIVATIVE; RAS PROTEIN; ENZYME INHIBITOR; HRAS PROTEIN, HUMAN; P21(RAS) FARNESYL PROTEIN TRANSFERASE; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; PROTEIN P21; TRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL MEMBRANE; CELL TRANSFORMATION; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN TISSUE; NONHUMAN; NUDE MOUSE; ONCOGENE RAS; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN PROCESSING; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENES, RAS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANSFERASES; TUMOR CELLS, CULTURED;

EID: 0031155980     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras : completing the framework of a signal transduction pathway. TIBS 1994 ; 19 : 279-83.
2. Spaargaren M, Bischoff JR, McCormick F. Signal transduction by Ras-like GTPases : a potential target for anticancer drugs. Gene Expression 1995 ; 4 : 345-56.
3. Barbacid M. Ras genes. Ann Rev Biochem 1987 ; 56 : 779-827.
4. Bos JL. ras oncogenes in human cancer : a review. Cancer Res 1989 ; 49 : 4682-9.
5. Shirazawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993 ; 26 : 85-8.
6. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ, Stanbridge EJ. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci USA 1996 ; 93 : 6665-70.
7. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice : synergetic action of oncogenes in vivo. Cell 1987 ; 49 : 465-75.
8. Watanabe M, Nobuta A, Tanaka J, Asaka M. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in Panc-1 pancreatic carcinoma cells. Int J Cancer 1996 ; 67 : 264-8.
9. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Spandidos DA. Rodent fibroblast tumors expressing myc and ras genes. Growth, metastasis and endogenous oncogene expression. Br J Cancer 1987 ; 56 : 251-9.
10. Rak J, Mitsuhashi Y, Erdos V, Huang S, Filmus J, Kerbel RS. Massive programmed cell death induced by three-dimensional growth conditions : suppression by mutant c-H-ras oncogene expression. J Cell Biol 1995 ; 131 : 1587-98.
11. Nooter K, Boersma AWM, Oostrum RG, Burger H, Jochemsen AG, Stoter G. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 1995 ; 71 : 556-61.
12. Fernandes RS, McGowan AJ, Cotter TG. Mutant H-ras overexpression inhibits drug and UV induced apoptosis. Anticancer Res 1996 ; 16 : 1691-706.
13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993 ; 74 : 957-67.
14. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirazawa S, Sasasuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression : implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995 ; 55 : 4575-80.
15. Cox AD, Der CJ. The ras/cholesterol connection : implications for ras oncogenicity. Crit Rev Oncogenesis 1992 ; 3 : 365-400.
16. Gutierrez L, Magee AI, Marshall CJ, Hancock JF. Post-translational processing of p21ras is two steps and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J 1989 ; 8 : 1093-8.
17. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990 ; 4 : 3319-28.
18. Moomaw JF, Casey PJ. Mammalian protein geranylgeranyltransferase. J Biol Chem 1992 ; 267 : 17438-43.
19. Perrin D, Halazy S, Hill BT. Inhibitors of the Ras signal transduction pathway as potential antitumour agents. J Enzyme Inhibition 1996 ; 11 : 77-95.
20. Graham SL. Inhibitors of protein farnesylation : a new approach to cancer chemotherapy. Exp Opin Ther Patents 1995 ; 5 : 1269-85.
21. Graham SL, Williams TM. inhibitors of protein farnesylation. Exp Opin Ther Patents 1996 ; 6 : 1295-304.
22. Kara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 1993 ; 90 : 2281-5.
23. Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa JI, et al. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl-protein transferase inhibitor. Jpn J Cancer Res 1996 ; 87 : 113-6.
24. Nagase T, Kawata S, Tamura S, Matsuda Y, Inui Y, Yamasaki E, et al. Inhibition of cell growth by a farnesyl protein transferase inhibitor : a preferential suppression of Ras farnesylation. Int J Cancer 1996 ; 65 : 620-6.
25. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, et al. Selective inhibition of farnesyl protein transferase blocks Ras processing in vivo. J Biol Chem 1993 ; 268 : 7617-20.
26. Lamothe M, Perrin D, Blotieres D, Leborgne M, Gras S, Bonnet D, et al. Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine. Bioorg Med Chem Lett 1996 ; 6 : 1291-6.
27. Cohen LH, Valentijn ARPM, Roodenburg L, Van Leeuwen REW, Holger Huisman R, Lutz RJ, et al. Different analogs of farnesyl pyrophosphate inhibit squalene synthase and protein : farnesyltransferase to different extents. Biochem Pharmacol 1995 ; 49 : 839-45.
28. Kothapalli R, Guthrie N, Chambers AF, Carroll KK. Farnesylamine : an inhibitor of farnesylation and growth of Ras-transformed cells. Lipids 1993 ; 28 : 969-73.
29. Manne V, Ricca CS, Gullo Brown J, Tuomari AV, Yan N, Patel D, et al. Ras farnesylation as a target for novel antitumor agents : potent and selective farnesyl diphosphate analogs inhibitors of farnesyltransferase. Drug Dev Res 1995 ; 34 : 121-37.
30. Patel DV, Gordon EM, Schmidt RJ, Weller HN, Young MG, Zahler R, et al. Phosphonyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase. J Med Chem 1995 ; 38 : 43542.
31. Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Gullo-Brown J, et al. Bisubstrate inhibitors of farnesyltransferase : a novel class of specific inhibitors of ras transformed cells. Oncogene 1995 ; 10 : 1763-79.
32. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res 1995 ; 55 : 3569-75.
33. Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, et al. Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem 1995 ; 270 : 30611-8.
34. Scholten JD, Zimmerman K, Oxender M, Sebolt-Leopold J, Gowan R, Leonard D, Hupe DJ. Inhibitors of farnesyl protein transferase-a possible cancer chemotherapeutic. Bioorg Med Chem 1996 ; 4 : 1537-43.
35. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl protein transferase by Cys-AAX peptides. Cell 1990 ; 62 : 81-8.
36. Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM. Non-farnesylated tetrapeptide inhibitors of protein farnesyl transferase. J Biol Chem 1991 ; 266 : 15575-8.
37. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, et al. Benzodiazepine peptidomimetics : potent inhibitors of Ras farnesylation in animal cells. Science 1993 ; 260 : 1937-42.
38. Kohl NE, Mosser SD, Jane deSolms S, Giuliani EA, Pompliano DL, Graham SL, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993 ; 260 : 1934-7.
39. Garcia AM, Rowell C, Ackerman K, Kowalczyk JJ, Lewis MD. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 1993 ; 268 : 18415-8.
40. Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, et al. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J Med Chem 1996 ; 39 : 353-8.
41. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995 ; 270 : 26802-6.
42. Kohl NE, Wilson FR, Mosser SD, Giuliani E, Jane deSolms S, Conner MW, et al. Protein farnesylfransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994 ; 91 : 9141-5.
43. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JS, Jane deSolms S, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1995 ; 1 : 792-6.
44. Sun J, Qian Y, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 1995 ; 55 : 4243-7.
45. Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, et al. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J Med Chem 1996 ; 39 : 224-36.
46. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res 1995 ; 55 : 5310-4.
47. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995 ; 55 : 5302-9.
48. Lerner EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995 ; 270 : 26770-3.
49. James GL, Goldstein JL, Brown MS, Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995 ; 270 : 6221-6.
50. Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem 1995 ; 270 : 7864-8.
51. Hall A. Ras-related GTPases and the cytoskeleton. Mol Biol Cell 1992 ; 3 : 475-9.
52. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995 ; 10 : 2289-96.
53. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci USA 1995 ; 92 : 11781-5.
54. Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 1995 ; 15 : 6613-22.
55. Prendergast GC, Davide JP, Jane deSolms S, Giuliani EA, Graham SL, Gibbs JB, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 1994 ; 14 : 4193-202.
56. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 1996 ; 56 : 1727-30.